1
|
Houssiau H, Pairet G, Dano H, Seront E. The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy. Curr Oncol 2023; 30:10550-10555. [PMID: 38132404 PMCID: PMC10742392 DOI: 10.3390/curroncol30120770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 12/11/2023] [Accepted: 12/12/2023] [Indexed: 12/23/2023] Open
Abstract
BACKGROUND Bladder cancer is a highly aggressive cancer, and muscle invasive urothelial carcinoma (MIUC) requires aggressive strategy. Concomitant chemo-radiotherapy (CRT) appears as a therapeutic option that allows bladder sparing. No biomarker is currently available to optimally select patients for CRT. METHODS We retrospectively enrolled patients with MIUC who were treated in a curative setting with CRT. Based on c-MET expression in pre-treatment tumor tissue, patients were stratified into two groups: no expression of c-MET (group A) and expression of c-MET (group B). We evaluated the outcome of these patients based on c-MET expression. RESULTS After a median follow-up of 40 months, 13 patients were enrolled in this analysis, 8 in group A and 5 in group B. The disease recurrence was 25% in group A and 100% in group B. Compared to group A, patients from group B experienced more frequent and more rapid recurrence in terms of metastases; the 3-year metastatic recurrence rate was 13% and 100%, respectively. The c-MET expression was also associated with a higher rate of cancer-related deaths. CONCLUSIONS In this retrospective analysis, c-MET expression was associated with worse disease-free survival and survival in patients treated radically with CRT.
Collapse
Affiliation(s)
- Hélène Houssiau
- Department of Medical Oncology, Groupe Jolimont, 7100 Haine Saint Paul, Belgium;
| | - Géraldine Pairet
- Department of Pathology, Groupe Jolimont, 7100 Haine Saint Paul, Belgium;
| | - Hélène Dano
- Department of Pathology, Cliniques Universitaires Saint Luc, 1200 Brussels, Belgium;
| | - Emmanuel Seront
- Department of Medical Oncology, Groupe Jolimont, 7100 Haine Saint Paul, Belgium;
| |
Collapse
|
2
|
Feng Y, Yang Z, Xu X. c-Met: A Promising Therapeutic Target in Bladder Cancer. Cancer Manag Res 2022; 14:2379-2388. [PMID: 35967753 PMCID: PMC9374328 DOI: 10.2147/cmar.s369175] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Accepted: 07/20/2022] [Indexed: 12/24/2022] Open
Abstract
Mesenchymal-epithelial transition factor (c-Met) belongs to the tyrosine kinase receptor family and is overexpressed in various human cancers. Its ligand is hepatocyte growth factor (HGF), and the HGF/c-Met signaling pathway is involved in a wide range of cellular processes, including cell proliferation, migration, and metastasis. Emerging studies have indicated that c-Met expression is strongly associated with bladder cancer (BCa) development and prognosis. Therefore, c-Met is a potential therapeutic target for BCa treatment. Recently, the aberrant expression of noncoding RNAs was found to play a significant role in tumour progression. There is a close connection between c-Met and noncoding RNA. Herein, we summarized the biological function and prognostic value of c-Met in BCa, as well as its potential role as a drug target. The relation of c-Met and ncRNA was also described in the paper.
Collapse
Affiliation(s)
- Yanfei Feng
- The Second Affiliated College, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China
| | - Zitong Yang
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China
| | - Xin Xu
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China
| |
Collapse
|
3
|
Zangoue M, Zangouei AS, Mojarrad M, Moghbeli M. MicroRNAs as the critical regulators of protein kinases in prostate and bladder cancers. EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS 2021. [DOI: 10.1186/s43042-021-00190-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Abstract
Background
Bladder cancer (BCa) and prostate cancer (PCa) are frequent urothelial and genital malignancies with a high ratio of morbidity and mortality which are more common among males. Since BCa and PCa cases are mainly diagnosed in advanced stages with clinical complications, it is required to introduce the efficient early detection markers. Protein kinases are critical factors involved in various cellular processes such as cell growth, motility, differentiation, and metabolism. Deregulation of protein kinases can be frequently observed through the neoplastic transformation and tumor progression. Therefore, kinases are required to be regulated via different genetic and epigenetic processes. MicroRNAs (miRNAs) are among the critical factors involved in epigenetic regulation of protein kinases. Since miRNAs are noninvasive and more stable factors in serum and tissues compared with mRNAs, they can be used as efficient diagnostic markers for the early detection of PCa and BCa.
Main body
In present review, we have summarized all of the reported miRNAs that have been associated with regulation of protein kinases in bladder and prostate cancers.
Conclusions
For the first time, this review highlights the miRNAs as critical factors in regulation of protein kinases during prostate and bladder cancers which paves the way of introducing a noninvasive kinase-specific panel of miRNAs for the early detection of these malignancies. It was observed that the class VIII receptors of tyrosine kinases and non-receptor tyrosine kinases were the most frequent targets for the miRNAs in bladder and prostate cancers, respectively.
Collapse
|
4
|
Zangouei AS, Barjasteh AH, Rahimi HR, Mojarrad M, Moghbeli M. Role of tyrosine kinases in bladder cancer progression: an overview. Cell Commun Signal 2020; 18:127. [PMID: 32795296 PMCID: PMC7427778 DOI: 10.1186/s12964-020-00625-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 07/02/2020] [Indexed: 12/20/2022] Open
Abstract
Background Bladder cancer (BCa) is a frequent urothelial malignancy with a high ratio of morbidity and mortality. Various genetic and environmental factors are involved in BCa progression. Since, majority of BCa cases are diagnosed after macroscopic clinical symptoms, it is required to find efficient markers for the early detection. Receptor tyrosine-kinases (RTKs) and non-receptor tyrosine-kinases (nRTKs) have pivotal roles in various cellular processes such as growth, migration, differentiation, and metabolism through different signaling pathways. Tyrosine-kinase deregulations are observed during tumor progressions via mutations, amplification, and chromosomal abnormalities which introduces these factors as important candidates of anti-cancer therapies. Main body For the first time in present review we have summarized all of the reported tyrosine-kinases which have been significantly associated with the clinicopathological features of BCa patients. Conclusions This review highlights the importance of tyrosine-kinases as critical markers in early detection and therapeutic purposes among BCa patients and clarifies the molecular biology of tyrosine-kinases during BCa progression and metastasis. Video abstract
Collapse
Affiliation(s)
- Amir Sadra Zangouei
- Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Amir Hossein Barjasteh
- Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Hamid Reza Rahimi
- Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Majid Mojarrad
- Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Meysam Moghbeli
- Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
| |
Collapse
|
5
|
c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression. Nat Commun 2019; 10:4349. [PMID: 31554791 PMCID: PMC6761206 DOI: 10.1038/s41467-019-12241-2] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Accepted: 08/27/2019] [Indexed: 01/03/2023] Open
Abstract
Treatment of muscle-invasive bladder cancer remains a major clinical challenge. Aberrant HGF/c-MET upregulation and activation is frequently observed in bladder cancer correlating with cancer progression and invasion. However, the mechanisms underlying HGF/c-MET-mediated invasion in bladder cancer remains unknown. As part of a negative feedback loop SMAD7 binds to SMURF2 targeting the TGFβ receptor for degradation. Under these conditions, SMAD7 acts as a SMURF2 agonist by disrupting the intramolecular interactions within SMURF2. We demonstrate that HGF stimulates TGFβ signalling through c-SRC-mediated phosphorylation of SMURF2 resulting in loss of SMAD7 binding and enhanced SMURF2 C2-HECT interaction, inhibiting SMURF2 and enhancing TGFβ receptor stabilisation. This upregulation of the TGFβ pathway by HGF leads to TGFβ-mediated EMT and invasion. In vivo we show that TGFβ receptor inhibition prevents bladder cancer invasion. Furthermore, we make a rationale for the use of combinatorial TGFβ and MEK inhibitors for treatment of high-grade non-muscle-invasive bladder cancers.
Collapse
|
6
|
Qiu J, Zeng F, Fang Y, Li J, Xiao S. Increased miR‐323a induces bladder cancer cell apoptosis by suppressing c‐Met. Kaohsiung J Med Sci 2019; 35:542-549. [PMID: 31180621 DOI: 10.1002/kjm2.12091] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Accepted: 05/06/2019] [Indexed: 02/06/2023] Open
Affiliation(s)
- Jun Qiu
- Department of OncologyHunan Province People's Hospital, the First Affiliated Hospital of Hunan Normal University Changsha Hunan People's Republic of China
| | - Fu‐Ren Zeng
- Department of OncologyHunan Province People's Hospital, the First Affiliated Hospital of Hunan Normal University Changsha Hunan People's Republic of China
| | - Yi Fang
- Department of AnesthesiologyChangsha Central Hospital Changsha Hunan People's Republic of China
| | - Jian Li
- Department of Radiotherapythe Second Affiliated Hospital of Guangxi Medical University Nanning People's Republic of China
| | - Sheng‐Ying Xiao
- Department of OncologyHunan Province People's Hospital, the First Affiliated Hospital of Hunan Normal University Changsha Hunan People's Republic of China
| |
Collapse
|
7
|
Xu X, Zhang G, He L, Zhu Y. Clinicopathological impacts of c-Met overexpression in bladder cancer: evidence from 1,336 cases. Onco Targets Ther 2019; 12:2695-2702. [PMID: 31114223 PMCID: PMC6497828 DOI: 10.2147/ott.s197540] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2018] [Accepted: 02/19/2019] [Indexed: 12/13/2022] Open
Abstract
Background: The clinicopathological impacts of c-Met overexpression in bladder cancer have been investigated in several studies with conflicting results. We performed this systematic review and meta-analysis to assess the pathologic and prognostic roles of c-Met status in bladder cancer patients. Methods: Eligible studies were searched and identified from the PubMed and China National Knowledge Infrastructure (CNKI) databases (up until October 4, 2018). The DerSimonian-Laird random-effects model was used to calculate the pooled risk estimates. Results: Eight studies including 1,336 bladder cancer cases were eventually included in this meta-analysis. We detected a significantly increased risk of poor overall survival (OS) associated with the high expression of c-Met (HR=2.42, 95% CI 1.36-4.32). There was no association between c-Met status and nuclear grade (OR=0.82, 95% CI 0.29-2.31) or tumor stage (OR=1.42, 95% CI 0.41-4.89). Conclusion: This study shows that the overexpression of c-Met in primary cancer tissues is associated with a worse OS in human bladder cancer. However, larger studies using standardized methods and criteria are warranted to verify these findings.
Collapse
Affiliation(s)
- Xin Xu
- Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
| | - Guanjun Zhang
- Department of Urology, Hospital of Traditional Chinese Medicine of Shangyu, Shangyu 312300, Zhejiang, People's Republic of China
| | - Liujia He
- Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
| | - Yi Zhu
- Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
| |
Collapse
|
8
|
Tsai T, Chen HE, Lin JF, Hwang TS, Lin YC, Chou KY, Hour MJ. A novel quinazoline derivative, MJ-56, exhibits phototoxicity toward human bladder cancer cells. UROLOGICAL SCIENCE 2018. [DOI: 10.4103/uros.uros_2_17] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
9
|
Davis B, Schwartz M, Duchemin D, Carl Barrett J, Post G. Validation of a Multiplexed Gene Signature Assay for Diagnosis of Canine Cancers from Formalin-Fixed Paraffin-Embedded Tissues. J Vet Intern Med 2017; 31:854-863. [PMID: 28370296 PMCID: PMC5435129 DOI: 10.1111/jvim.14686] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 01/05/2017] [Accepted: 02/07/2017] [Indexed: 01/09/2023] Open
Abstract
Background Use of molecular‐based diagnostics for companion animals is impeded by availability of technology platforms, tissue acquisition requirements, and species‐specific reagents. Hypothesis/Objectives To validate a quantitative nuclease protection assay (qNPA) to simultaneously measure RNA expression of multiple genes in archived formalin‐fixed paraffin‐embedded (FFPE) tumors from dogs. Animals All tumor biopsy samples were collected retrospectively from surgical biopsies and in the care of veterinarians. Methods Retrospective case series. A qNPA 96‐well ArrayPlate was built using 30 canine‐specific genes, 5 housekeeping genes, positive and negative controls with qualified gene‐specific oligonucleotides. Pearson's correlation, coefficient of variation (CV), and multivariate analysis were used to determine analytical performance using 40 FFPE dog tumors. Once validated, 70 FFPE dog tumors were analyzed for differences in gene expression using hierarchical clustering and analysis of variance of log transformed data. Immunohistochemistry (IHC) was performed to correlate gene expression and protein expression in a subset of tumors. Results The assay was linear with decreasing sample input (R2 = 0.978), reproducible within and between 96‐well plates (r = 0.988 and 0.95, respectively) and between different laboratories (CV = 0.96). Hierarchical cluster analysis showed grouping of tumors by histogenesis and oncogenes. Significant differences were found between BCl2, E2F transcription factor 1, MDM2, COX‐2, MET proto‐oncogene receptor kinase, and other biologically relevant gene expression in tumor subtypes. Immunohistochemistry confirmed protein expression. Conclusions and Clinical Implications Because this technology works reliably on FFPE specimens, it can help expedite the broad introduction of multiplexed genomic information for improved diagnostics and discovery of new targets for therapies in veterinary oncology.
Collapse
Affiliation(s)
| | | | - D Duchemin
- Innogenics Inc, Harvard, MA.,Veterinary Cancer Center, Norwalk, CT
| | | | - G Post
- Innogenics Inc, Harvard, MA.,Veterinary Cancer Center, Norwalk, CT
| |
Collapse
|
10
|
Medal RM, Im AM, Yamamoto Y, Lakhdari O, Blackwell TS, Hoffman HM, Sahoo D, Prince LS. The innate immune response in fetal lung mesenchymal cells targets VEGFR2 expression and activity. Am J Physiol Lung Cell Mol Physiol 2017; 312:L861-L872. [PMID: 28336813 PMCID: PMC5495951 DOI: 10.1152/ajplung.00554.2016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 03/15/2017] [Accepted: 03/16/2017] [Indexed: 02/06/2023] Open
Abstract
In preterm infants, soluble inflammatory mediators target lung mesenchymal cells, disrupting airway and alveolar morphogenesis. However, how mesenchymal cells respond directly to microbial stimuli remains poorly characterized. Our objective was to measure the genome-wide innate immune response in fetal lung mesenchymal cells exposed to the bacterial endotoxin lipopolysaccharide (LPS). With the use of Affymetrix MoGene 1.0st arrays, we showed that LPS induced expression of unique innate immune transcripts heavily weighted toward CC and CXC family chemokines. The transcriptional response was different between cells from E11, E15, and E18 mouse lungs. In all cells tested, LPS inhibited expression of a small core group of genes including the VEGF receptor Vegfr2 Although best characterized in vascular endothelial populations, we demonstrated here that fetal mouse lung mesenchymal cells express Vegfr2 and respond to VEGF-A stimulation. In mesenchymal cells, VEGF-A increased cell migration, activated the ERK/AKT pathway, and promoted FOXO3A nuclear exclusion. With the use of an experimental coculture model of epithelial-mesenchymal interactions, we also showed that VEGFR2 inhibition prevented formation of three-dimensional structures. Both LPS and tyrosine kinase inhibition reduced three-dimensional structure formation. Our data suggest a novel mechanism for inflammation-mediated defects in lung development involving reduced VEGF signaling in lung mesenchyme.
Collapse
Affiliation(s)
- Rachel M Medal
- Department of Pediatrics, University of California, San Diego, and Rady Children's Hospital, San Diego, California; and
| | - Amanda M Im
- Departments of Pediatrics, Medicine, Developmental and Cell Biology, and Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Yasutoshi Yamamoto
- Departments of Pediatrics, Medicine, Developmental and Cell Biology, and Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Omar Lakhdari
- Department of Pediatrics, University of California, San Diego, and Rady Children's Hospital, San Diego, California; and
| | - Timothy S Blackwell
- Departments of Pediatrics, Medicine, Developmental and Cell Biology, and Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Hal M Hoffman
- Department of Pediatrics, University of California, San Diego, and Rady Children's Hospital, San Diego, California; and
| | - Debashis Sahoo
- Department of Pediatrics, University of California, San Diego, and Rady Children's Hospital, San Diego, California; and
| | - Lawrence S Prince
- Department of Pediatrics, University of California, San Diego, and Rady Children's Hospital, San Diego, California; and
| |
Collapse
|
11
|
Ramsey SA, Xu T, Goodall C, Rhodes AC, Kashyap A, He J, Bracha S. Cross-species analysis of the canine and human bladder cancer transcriptome and exome. Genes Chromosomes Cancer 2017; 56:328-343. [DOI: 10.1002/gcc.22441] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Revised: 12/27/2016] [Accepted: 12/29/2016] [Indexed: 02/06/2023] Open
Affiliation(s)
- Stephen A. Ramsey
- Department of Biomedical Sciences; Oregon State University; Corvallis Oregon USA
- School of Electrical Engineering and Computer Science; Oregon State University; Corvallis Oregon USA
| | - Tanjin Xu
- Department of Biomedical Sciences; Oregon State University; Corvallis Oregon USA
- School of Electrical Engineering and Computer Science; Oregon State University; Corvallis Oregon USA
| | - Cheri Goodall
- Department of Clinical Sciences; Oregon State University; Corvallis Oregon USA
| | - Adelaide C. Rhodes
- Department of Biomedical Sciences; Oregon State University; Corvallis Oregon USA
- Center for Genome Research and Biocomputing, Oregon State University; Corvallis Oregon USA
| | - Amita Kashyap
- Department of Biomedical Sciences; Oregon State University; Corvallis Oregon USA
| | - Jun He
- Department of Biomedical Sciences; Oregon State University; Corvallis Oregon USA
- School of Electrical Engineering and Computer Science; Oregon State University; Corvallis Oregon USA
| | - Shay Bracha
- Department of Clinical Sciences; Oregon State University; Corvallis Oregon USA
| |
Collapse
|